201 related articles for article (PubMed ID: 36243494)
41. Estrogen Receptor-Targeted and Progesterone Receptor-Targeted PET for Patients with Breast Cancer.
Ulaner GA; Fowler AM; Clark AS; Linden H
PET Clin; 2023 Oct; 18(4):531-542. PubMed ID: 37270377
[TBL] [Abstract][Full Text] [Related]
42. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
43. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
[TBL] [Abstract][Full Text] [Related]
44. 18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis.
Evangelista L; Guarneri V; Conte PF
Curr Radiopharm; 2016; 9(3):244-257. PubMed ID: 27774910
[TBL] [Abstract][Full Text] [Related]
45. 18F-Fluoroestradiol PET in the evaluation of probable oligometastatic breast cancer.
Denton M; Taubman K; Sutherland T
J Med Imaging Radiat Oncol; 2021 Jun; 65(3):333-334. PubMed ID: 33369181
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of tumour heterogeneity by
Liu C; Hu S; Xu X; Zhang Y; Wang B; Song S; Yang Z
Breast Cancer Res; 2022 Aug; 24(1):57. PubMed ID: 36028895
[TBL] [Abstract][Full Text] [Related]
47. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
[TBL] [Abstract][Full Text] [Related]
48. Diagnostic accuracy and safety of 16α-[
Chae SY; Ahn SH; Kim SB; Han S; Lee SH; Oh SJ; Lee SJ; Kim HJ; Ko BS; Lee JW; Son BH; Kim J; Ahn JH; Jung KH; Kim JE; Kim SY; Choi WJ; Shin HJ; Gong G; Lee HS; Lee JB; Moon DH
Lancet Oncol; 2019 Apr; 20(4):546-555. PubMed ID: 30846327
[TBL] [Abstract][Full Text] [Related]
49.
Salem K; Kumar M; Powers GL; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
Radiology; 2018 Mar; 286(3):856-864. PubMed ID: 28956736
[TBL] [Abstract][Full Text] [Related]
50. Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model.
Paquette M; Phoenix S; Ouellet R; Langlois R; van Lier JE; Turcotte EE; Bénard F; Lecomte R
Mol Imaging Biol; 2013 Oct; 15(5):625-32. PubMed ID: 23619898
[TBL] [Abstract][Full Text] [Related]
51. Can
Gupta M; Datta A; Choudhury PS; Dsouza M; Batra U; Mishra A
World J Nucl Med; 2017; 16(2):133-139. PubMed ID: 28553180
[TBL] [Abstract][Full Text] [Related]
52. Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression.
Currin E; Peterson LM; Schubert EK; Link JM; Krohn KA; Livingston RB; Mankoff DA; Linden HM
J Natl Compr Canc Netw; 2016 Feb; 14(2):144-7. PubMed ID: 26850484
[TBL] [Abstract][Full Text] [Related]
53. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
[TBL] [Abstract][Full Text] [Related]
54. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.
Sun Y; Yang Z; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
PLoS One; 2015; 10(1):e0116341. PubMed ID: 25617853
[TBL] [Abstract][Full Text] [Related]
55. 18F-FES PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive Breast Cancer: Two Representative Cases and Review of the Literature.
Bodapati S; Abraham P; Chen A; Guilbault D; McDonald M; Matro J; Shatsky R; Obrzut S
Tomography; 2022 Apr; 8(2):1060-1065. PubMed ID: 35448720
[TBL] [Abstract][Full Text] [Related]
56. 18F-Fluoroestradiol PET/CT Correctly Diagnosed 18F-FDG-Avid Inflammatory Lymph Nodes in a Patient With Estrogen Receptor-Positive Breast Cancer.
Yamane T; Ueda S; Seto A; Kuji I
Clin Nucl Med; 2018 May; 43(5):379-380. PubMed ID: 29485433
[TBL] [Abstract][Full Text] [Related]
57. Increased 18 F-Fluoroestradiol Uptake of Radiation Pneumonitis in a Patient With Metastatic Breast Cancer.
Pan B; Hao Z; Zhou Y; Sun Q; Huo L
Clin Nucl Med; 2023 May; 48(5):437-438. PubMed ID: 36800243
[TBL] [Abstract][Full Text] [Related]
58. Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments?
Linden HM; Mankoff DA
Clin Cancer Res; 2023 Jun; 29(11):2015-2016. PubMed ID: 36988617
[TBL] [Abstract][Full Text] [Related]
59. Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer
Paquette M; Lavallée É; Phoenix S; Ouellet R; Senta H; van Lier JE; Guérin B; Lecomte R; Turcotte ÉE
J Nucl Med; 2018 Feb; 59(2):197-203. PubMed ID: 28798032
[TBL] [Abstract][Full Text] [Related]
60. Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.
Peterson LM; Kurland BF; Link JM; Schubert EK; Stekhova S; Linden HM; Mankoff DA
Nucl Med Biol; 2011 Oct; 38(7):969-78. PubMed ID: 21982568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
